Steroid hormone intervenes in the endometrial tumorigenesis of Pten ablation

다국어 초록 (Multilingual Abstract)

Endometrial cancer, the most common gynecological cancer, is closely associated with endometrial hyperplasia, unopposed estrogen exposure, and genetic alterations. Phosphatase and tensin homologue (PTEN) is a tumor suppressor genes completely lost or mutated in >50% of primary endometrioid endometrial cancers. Estrogen-dependent endometrioid carcinoma is the most common type of endometrial cancer. Progesterone is a hormone that antagonizes the growth-promoting properties of estrogen in the uterus. Progestin is used as a conservative endocrine treatment of early endometrial cancer in order to preserve fertility as well as a palliative measure for advanced-stage patients. Progesterone therapy has been shown to be effective in preventing endometrial cancer as well as controlling growth of the endometrium. However, the effectiveness of progestin for women with endometrial cancer is less clear. In order to understand the effect of steroid hormone on endometrial cancer progression, we used a mouse endometrial cancer model with conditional loss of Pten in the mouse uterus (PRcre/+Ptenf/f, Ptend/d). To assess the effect of steroid hormones, ovariectomized Ptenf/f and Ptend/d mice were treated with estrogen or progesterone over a period of three month. Uterine weight gain was significantly decreased in ovariectomized PRcre/+Ptenf/f mice compared to intact PRcre/+Ptenf/fmice. Ovariectomized PRcre/+Ptenf/fmice treated with P4 or vehicle also exhibited decreased uterine cancer size compared with intact PRcre/+Ptenf/f mice. Proliferation of ovariectomized PRcre/+Ptenf/fmice treated with P4 is highly decreased compared to other groups. The levels of stromal progesterone receptor were highly increased in ovariectomized PRcre/+Ptenf/fmice treated with P4 which resulted in decreased epithelial proliferation. Therefore, these results suggest that P4 treatment significantly reduces tumor mass but does not affect cancer progression in PRcre/+Ptenf/fmice.

참고문헌 (Reference)

1 Kim TH, "The synergistic effect of Mig-6 and Pten ablation on endometrial cancer development and progression" 29 : 3770-3780, 2010

2 Vivanco I, "The phosphatidylinositol 3-Kinase AKT pathway in human cancer" 2 : 489-501, 2002

3 Martin L, "The inhibition by progesterone of uterine epithelial proliferation in the mouse" 57 : 549-554, 1973

4 Li Q, "The antiproliferative action of progesterone in uterine epithelium is mediated by Hand2" 331 : 912-916, 2011

5 Kurita T, "Stromal progesterone receptors mediate the inhibitory effects of progesterone on estrogen-induced uterine epithelial cell deoxyribonucleic acid synthesis" 139 : 4708-4713, 1998

6 Ehrlich CE, "Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium" 158 : 796-807, 1988

7 Kim JJ, "Role of progesterone in endometrial cancer" 28 : 81-90, 2010

8 Guzeloglu-Kayisli O, "Regulation of PTEN (phosphatase and tensin homolog deleted on chromosome 10) expression by estradiol and progesterone in human endometrium" 88 : 5017-5026, 2003

9 Fukuda K, "Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma" 69 : 220-225, 1998

10 Iwai K, "Prognostic significance of progesterone receptor immunohistochemistry for lymph node metastases in endometrial carcinoma" 72 : 351-359, 1999

11 Levine RL, "PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma" 58 : 3254-3258, 1998

12 Fyles A, "Neither ovariectomy nor progestin treatment prevents endometrial neoplasia in pten＋/− mice" 108 : 395-401, 2008

13 Sun H, "Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia" 115 : 32-38, 2001

14 Maxwell GL, "Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias" 58 : 2500-2503, 1998

15 Kaunitz AM, "Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians" 43 : 73-83, 1998

16 Ziel HK, "Increased risk of endometrial carcinoma among users of conjugated estrogens" 293 : 1167-1170, 1975

17 Carcangiu ML, "Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part I: Clinical and histologic correlations" 94 : 247-254, 1990

18 Martin L, "Hypertrophy and hyperplasia in the mouse uterus after oestrogen treatment: an autoradiographic study" 56 : 133-144, 1973

19 Ramirez PT, "Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review" 95 : 133-138, 2004

20 Yamazawa K, "Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer" 22 : 1953-1958, 2007

21 Samulak D, "Evaluation of Expression of the PTEN Gene, Oestrogen and Progesterone Receptors as Diagnostic and Predictive Factors in Endometrial Cancer" 2013

22 Jick SS, "Estrogens, progesterone, and endometrial cancer" 4 : 20-24, 1993

23 Nyholm HC, "Estrogen and progesterone receptors in endometrial carcinoma: comparison of immunohistochemical and biochemical analysis" 12 : 246-252, 1993

24 Kleine W, "Estrogen and progesterone receptors in endometrial cancer and their prognostic relevance" 38 : 59-65, 1990

25 Joshi A, "Endometrial tumorigenesis in Pten(＋/−) mice is independent of coexistence of estrogen and estrogen receptor alpha" 180 : 2536-2547, 2012

26 Deligdisch L, "Endometrial carcinoma: two diseases?" 10 : 237-246, 1987

27 Hale GE, "Endometrial cancer: hormonal factors, the perimenopausal “window of risk”, and isoflavones" 87 : 3-15, 2002

28 Benshushan A, "Endometrial adenocarcinoma in young patients: evaluation and fertility-preserving treatment" 117 : 132-137, 2004

29 Di Cristofano A, "Endometrial Carcinoma" 2 : 57-85, 2007

30 Jabbour HN, "Endocrine regulation of menstruation" 27 : 17-46, 2006

31 Chambliss KL, "ERbeta has nongenomic action in caveolae" 16 : 938-946, 2002

32 Kim TH, "Critical tumor suppressor function mediated by epithelial Mig-6 in endometrial cancer" 73 : 5090-5099, 2013

33 Lesche R, "Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene" 32 : 148-149, 2002

34 Soyal SM, "Cre-mediated recombination in cell lineages that express the progesterone receptor" 41 : 58-66, 2005

35 Hahn HS, "Conservative treatment with progestin and pregnancy outcomes in endometrial cancer" 19 : 1068-1073, 2009

36 Kaku T, "Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome" 167 : 39-48, 2001

37 Daikoku T, "Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice" 68 : 5619-5627, 2008

38 Minaguchi T, "Combined phospho-Akt and PTEN expressions associated with post-treatment hysterectomy after conservative progestin therapy in complex atypical hyperplasia and stage Ia, G1 adenocarcinoma of the endometrium" 248 : 112-122, 2007

39 Jick SS, "Combined estrogen and progesterone use and endometrial cancer" 4 : 384-, 1993

40 Huet-Hudson YM, "Cell type-specific localization of c-myc protein in the mouse uterus: modulation by steroid hormones and analysis of the periimplantation period" 125 : 1683-1690, 1989

41 Siegel R, "Cancer statistics, 2013" 63 : 11-30, 2013

42 Paria BC, "Blastocyst's state of activity determines the “window” of implantation in the receptive mouse uterus" 90 : 10159-10162, 1993

43 Hoekstra AV, "Absence of progesterone receptors in a failed case of fertility-sparing treatment in early endometrial cancer: a case report" 53 : 869-873, 2008

44 Piver MS, "A prospective trial of progesterone therapy for malignant peritoneal cytology in patients with endometrial carcinoma" 47 : 373-376, 1992